[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579129":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":36,"locations":43,"responsibleParty":61,"collaborators":24,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":95,"whyStopped":24,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Victor Chang Cardiac Research Institute","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirzepatide 2.5mg weekly","EXPERIMENTAL","Administered subcutaneously.",[13],"Drug: Tirzepatide 2.5mg weekly",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo injection (normal saline)",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tirzepatide 2.5 mg\u002F0.5 mL solution for injection vial or pre-filled pen. Each vial\u002F pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)\n\nTirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses.",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Placebo injection (normal saline)","Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.",[15],[30,33],{"name":31,"affiliation":5,"role":32},"Jennifer R Snaith, MD PHD","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":5,"role":35},"Jerry R Greenfield, MD PHD","STUDY_DIRECTOR",[37,41],{"name":31,"role":38,"phone":39,"phoneExt":24,"email":40},"CONTACT","+61 2 9295 8600","j.snaith@victorchang.edu.au",{"name":34,"role":38,"phone":24,"phoneExt":24,"email":42},"j.greenfield@victorchang.edu.au",[44],{"facility":5,"status":24,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Sydney","New South Wales","2010","Australia","AU",{"type":51,"coordinates":52},"Point",[53,54],151.20732,-33.86785,{"lat":54,"lon":53},[57,60],{"name":58,"role":38,"phone":59,"phoneExt":24,"email":40},"Jennifer R Snaith, MD\u002FPhD","61 2 9295 8600",{"name":31,"role":32,"phone":24,"phoneExt":24,"email":24},{"type":62,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100579129","phase-2-acute-metabolic-effects-of-tirzepatide-in-type-1-diabetes-100579129",false,"NCT06820281","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)","TIRTLE2","Inclusion Criteria:\n\n* age 18-65 years\n* BMI ≥ 27 kg\u002Fm2\n* HbA1c ≤ 9.0%\n* insulin delivery using an automated insulin delivery system\n* at least 2 years since diagnosis of type 1 diabetes\n\nExclusion Criteria:\n\n* TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; steroids, antipsychotics, immunosuppressants in the last 6 weeks.\n* Hypoglycemic unawareness or severe hypoglycemia last 6 months.\n* History of seizure disorder.\n* History of weight loss surgery.\n* eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m2.\n* Liver disease (known cirrhosis, LFTs \\> 3x upper limit of normal).\n* Active malignancy.\n* Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception.\n* History of cardiovascular disease, or coronary event or stroke in last 3 months\n* Hemoglobin level \\\u003C 13.5 g\u002FdL in men, \\\u003C 12.0 g\u002FdL in women","ALL","18 Years","65 Years",{"count":75,"type":76},44,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.",[82],"Type 1 Diabetes Mellitus",[84,85,86,87,88,89,90,91,92,93,94],"Diabetes Mellitus, Type 1","Diabetes Mellitus","Autoimmune Diseases","Incretins","Physiological Effects of Drugs","Tirzepatide","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Diseases","Overnutrition","Insulin Resistance","NOT_YET_RECRUITING","2026-05-17",{"date":98,"type":99},"2026-05-19","ACTUAL",{"date":101,"type":76},"2026-07-01",{"date":103,"type":76},"2027-12-31",{"name":5,"class":6},1]